摘要: |
Baloxavir marboxil是由日本盐野义制药(Shionogi)研发的一种新型抗流感药物。其于2018年2月在日本上市,用于治疗甲型和乙型流感病毒引起的流行性感冒。相比于其他抗流感药物,baloxavir marboxil抗病毒作用机制独特,1次只需口服1片,不良反应少,患者依从性好。本文就该药的作用机制、药效学、药代动力学、临床试验等方面进行综述。 |
关键词: 抗流感药物 baloxavir marboxil RNA聚合酶 cap依赖型内切酶抑制剂 药代动力学 药效学 临床试验 |
DOI: |
分类号: |
基金项目: |
|
Research on new anti-influenza drug baloxavir marboxil |
TAO Jia-jia, LYU Qian-zhou, LI Xiao-yu, DAI Pei-fang, YE Yan-rong, SHEN Yun*
|
Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032, China
|
Abstract: |
Baloxavir marboxil is a new anti-influenza drug developed by Shionogi in Japan. It was launched in Japan in February 2018 for the treatment of influenza caused by influenza A and B viruses. Compared with other anti-influenza drugs, baloxavir marboxil has a unique anti-viral mechanism, requiring only one oral dose at a time, with fewer side effects and good patient compliance. In this review, the mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials, and so on of this medicine were discussed. |
Key words: anti-influenza drugs baloxavir marboxil RNA polymerase cap-dependent endonuclease inhibitor pharmacodynamics pharmacokinetics clinical trials |